Related Experiment Video
Updated: May 26, 2026
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Ruxolitinib for the treatment of myelofibrosis
A Ostojic1, R Vrhovac, S Verstovsek
1Department of Hematology, University Hospital Merkur, University of Zagreb School of Medicine, Zagreb, Croatia.
Abstract:
Ruxolitinib is an orally available, ATP-competitive inhibitor, selective for tyrosine-protein kinases JAK1 and JAK2 and is the most advanced JAK1/JAK2 inhibitor in development for the treatment of myeloproliferative neoplasms. The suggested mechanism of action of ruxolitinib is attenuation of cytokine signaling via the inhibition of JAK1 and JAK2 (wild-type or mutated forms), resulting in antiproliferative and proapoptotic effects. In the phase III COMFORT-I trial conducted in patients with myelofibrosis, ruxolitinib demonstrated durable reductions in splenomegaly. The proportion of patients that achieved spleen volume reduction ≥ 35% from baseline to 24 weeks was 41.9 % with ruxolitinib versus 0.7% with placebo (P < 0.0001), as evaluated by magnetic resonance imaging or computed tomography. In the phase III COMFORT-II trial, reductions in spleen volume ≥ 35% were observed in 31.9% of patients treated with ruxolitinib versus 0% with best available therapy at week 24, and 28.5% versus 0% at week 48 (both P < 0.0001). Low toxicity, alleviation of constitutional symptoms, weight gain and improvement in general physical condition were observed with ruxolitinib treatment which may substantially improve quality of life in patients with myelofibrosis.
Insights
Ruxolitinib significantly reduced spleen size in myelofibrosis patients. This Janus kinase (JAK) inhibitor also improved symptoms and quality of life, offering a new treatment option.
Area of Science:
- Pharmacology and Oncology
- Biochemistry and Molecular Biology
Background:
- Myeloproliferative neoplasms (MPNs) are a group of diseases characterized by the overproduction of myeloid cells.
- Ruxolitinib is an orally available inhibitor targeting Janus kinases (JAK) 1 and 2, crucial in cytokine signaling pathways implicated in MPNs.
Purpose of the Study:
- To evaluate the efficacy and safety of ruxolitinib in patients with myelofibrosis, a serious MPN.
- To assess ruxolitinib's impact on splenomegaly, constitutional symptoms, and overall quality of life.
Main Methods:
- Phase III clinical trials (COMFORT-I and COMFORT-II) were conducted in patients with myelofibrosis.
- Treatment arms included ruxolitinib, placebo, and best available therapy.
- Spleen volume reduction was assessed using imaging (MRI/CT), and symptom burden was monitored.
Main Results:
- Ruxolitinib demonstrated significant and durable reductions in spleen volume compared to placebo and best available therapy (e.g., 41.9% vs 0.7% reduction ≥35% at 24 weeks in COMFORT-I).
- Patients treated with ruxolitinib experienced alleviation of constitutional symptoms, weight gain, and improved physical condition.
- The treatment was associated with low toxicity.
Conclusions:
- Ruxolitinib is an effective treatment for myelofibrosis, significantly reducing spleen size and improving patient-reported outcomes.
- The observed benefits, including symptom relief and improved quality of life, support ruxolitinib's role in managing myelofibrosis.
Related Concept Videos
02:56Treatment Resistent Cancers
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
02:56Treatment Resistant Cancers
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF